Mia Øgaard Mønsted
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mia Øgaard Mønsted has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Martin Haupt-Jorgensen
The Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen, Denmark
4 shared publications Karsten Buschard
The Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen, Denmark
3 shared publications- Flemming Pociot
Translational Type 1 Diabetes Research, Department of Clinical Research, Steno Diabetes Center Copenhagen
2 shared publications - Karsten Buschard
Faculty of Health and Medical Sciences, University of Copenhagen, DK-1870 Copenhagen, Denmark
2 shared publications - Kristina Pedersen
The Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen, Denmark
2 shared publications Laurits Juulskov Holm
Affiliation Department of Pathology, Rigshospitalet, The Bartholin Institute, Copenhagen, Denmark
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (6)
Microbiota Regulates Phosphatidylcholine in the Intestinal Mucus Lipidome of Mice in a Strain‐ and Segment‐Dependent Manner
Background: Type 1 diabetes (T1D) is associated with intestinal barrier dysfunction, which depends on an intact mucus layer. Phosphatidylcholine (PC) is a major lipid of intestinal mucus that likely exerts an important barrier function due to its hydrophobic and anti‐inflammatory properties. Recently, we showed that PC is reduced in jejunal and colonic mucus in pre‐diabetic non‐obese diabetic (NOD) mice compared to C57BL/6 (B6) mice. As such, PC may play a protective role in T1D. Some bacteria produce PC. However, it is unknown whether T1D‐associated dysbiosis (i.e., altered microbial composition) is behind the reduced PC content in the intestine. Methods: Here, we examined the impact of gut microbiota on jejunal and colonic mucus PC composition. This was done by treating 4 weeks old pre‐diabetic NOD and B6 mice with a broad‐spectrum antibiotic cocktail and by breeding germ‐free BALB/c mice, which were then compared with untreated barrier‐housed NOD, B6 and BALB/c mice. The intestinal mucus lipid profile was analysed by quantitative shotgun lipidomics, while the relative composition of the faecal microbiota was assessed by 16S rRNA gene amplicon sequencing and verified by absolute quantifications using qPCR. Results: Comparing jejunum and colon from the mice revealed that the overall intestinal mucus lipidome was segment‐ but not strain‐specific. Antibiotic treatment reduced colonic PC levels in the NOD and B6 mice, whereas germ‐free conditions did not in the BALB/c mice, which, independent of the presence of microbiota, had the lowest levels of colon PC. The faecal microbiome composition also differed between the three strains of untreated barrier‐housed mice, including reduced abundance of phyla with PC‐containing bacteria in the BALB/c mice. Conclusions: Results suggest that gut microbiota perturbation is an important determinant of intestinal mucus PC content, although the effect seems to depend on the host‐specific baseline microbiota composition.
- 10 November 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (6)
Open AccessMicrobiota Regulates Phosphatidylcholine in the Intestinal Mucus Lipidome of Mice in a Strain‐ and Segment‐Dependent Manner
Background: Type 1 diabetes (T1D) is associated with intestinal barrier dysfunction, which depends on an intact mucus layer. Phosphatidylcholine (PC) is a major lipid of intestinal mucus that likely exerts an important barrier function due to its hydrophobic and anti‐inflammatory properties. Recently, we showed that PC is reduced in jejunal and colonic mucus in pre‐diabetic non‐obese diabetic (NOD) mice compared to C57BL/6 (B6) mice. As such, PC may play a protective role in T1D. Some bacteria produce PC. However, it is unknown whether T1D‐associated dysbiosis (i.e., altered microbial composition) is behind the reduced PC content in the intestine. Methods: Here, we examined the impact of gut microbiota on jejunal and colonic mucus PC composition. This was done by treating 4 weeks old pre‐diabetic NOD and B6 mice with a broad‐spectrum antibiotic cocktail and by breeding germ‐free BALB/c mice, which were then compared with untreated barrier‐housed NOD, B6 and BALB/c mice. The intestinal mucus lipid profile was analysed by quantitative shotgun lipidomics, while the relative composition of the faecal microbiota was assessed by 16S rRNA gene amplicon sequencing and verified by absolute quantifications using qPCR. Results: Comparing jejunum and colon from the mice revealed that the overall intestinal mucus lipidome was segment‐ but not strain‐specific. Antibiotic treatment reduced colonic PC levels in the NOD and B6 mice, whereas germ‐free conditions did not in the BALB/c mice, which, independent of the presence of microbiota, had the lowest levels of colon PC. The faecal microbiome composition also differed between the three strains of untreated barrier‐housed mice, including reduced abundance of phyla with PC‐containing bacteria in the BALB/c mice. Conclusions: Results suggest that gut microbiota perturbation is an important determinant of intestinal mucus PC content, although the effect seems to depend on the host‐specific baseline microbiota composition.
- Open Access
- 13 November 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 193, 118744
Evaluation of the pharmacological cathepsin S inhibitor LY3000328 on autoimmune diabetes in mice
- 13 November 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 193, 118744
Open AccessEvaluation of the pharmacological cathepsin S inhibitor LY3000328 on autoimmune diabetes in mice
- Open Access
- 15 July 2025
- Published by Elsevier in Immunology Letters
- Vol. 276, 107060
Genetic and transcriptional dysregulation of innate antiviral immune pathways in type 1 diabetes
- 15 July 2025
- Published by Elsevier in Immunology Letters
- Vol. 276, 107060
Open AccessGenetic and transcriptional dysregulation of innate antiviral immune pathways in type 1 diabetes
- Open Access
- 8 September 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (9) , e0289258
Failure to replicate the diabetes alleviating effect of a maternal gluten-free diet in non-obese diabetic mice
Type 1 diabetes (T1D) is an autoimmune disease with an unexplained rising incidence for which environmental factors like gluten may play a role. Previously, we showed that a gluten-free (GF) diet provided strictly in utero reduces the autoimmune diabetes incidence in Non-Obese Diabetic (NOD) mice compared to a gluten-containing standard (STD) diet. The current study was initiated to elucidate possible mechanisms behind the diabetes-alleviating effect of the same diet intervention. NOD mice received either a GF Altromin diet or a STD Altromin diet during pregnancy. Female offspring from both groups were fed a STD diet throughout life and their diabetes incidence was recorded for 200 days. The following parameters were measured in 13-week-old female offspring: insulitis degree, glucose and insulin tolerance, and plasma insulin autoantibody titer. The diet intervention showed no reduction in autoimmune diabetes incidence, insulitis degree, glucose nor insulin tolerance and plasma insulin autoantibody titer. In conclusion, this study could not replicate the previously observed diabetes alleviative effects of a maternal gluten-free diet in NOD mouse offspring and could therefore not further elucidate potential mechanisms.
- 8 September 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (9) , e0289258
Open AccessFailure to replicate the diabetes alleviating effect of a maternal gluten-free diet in non-obese diabetic mice
Type 1 diabetes (T1D) is an autoimmune disease with an unexplained rising incidence for which environmental factors like gluten may play a role. Previously, we showed that a gluten-free (GF) diet provided strictly in utero reduces the autoimmune diabetes incidence in Non-Obese Diabetic (NOD) mice compared to a gluten-containing standard (STD) diet. The current study was initiated to elucidate possible mechanisms behind the diabetes-alleviating effect of the same diet intervention. NOD mice received either a GF Altromin diet or a STD Altromin diet during pregnancy. Female offspring from both groups were fed a STD diet throughout life and their diabetes incidence was recorded for 200 days. The following parameters were measured in 13-week-old female offspring: insulitis degree, glucose and insulin tolerance, and plasma insulin autoantibody titer. The diet intervention showed no reduction in autoimmune diabetes incidence, insulitis degree, glucose nor insulin tolerance and plasma insulin autoantibody titer. In conclusion, this study could not replicate the previously observed diabetes alleviative effects of a maternal gluten-free diet in NOD mouse offspring and could therefore not further elucidate potential mechanisms.
- Open Access
- 1 August 2021
- Published by Elsevier in Journal of Autoimmunity
- Vol. 122, 102674
Intestinal permeability in type 1 diabetes: An updated comprehensive overview
- 1 August 2021
- Published by Elsevier in Journal of Autoimmunity
- Vol. 122, 102674
Open AccessIntestinal permeability in type 1 diabetes: An updated comprehensive overview
- Open Access
- 9 January 2020
- Published by Wiley in PPAR Research
- Vol. 2020, 1-11
PPARs and the Development of Type 1 Diabetes
Peroxisome proliferator-activated receptors (PPARs) are a family of transcription factors with a key role in glucose and lipid metabolism. PPARs are expressed in many cell types including pancreatic beta cells and immune cells, where they regulate insulin secretion and T cell differentiation, respectively. Moreover, various PPAR agonists prevent diabetes in the non-obese diabetic (NOD) mouse model of type 1 diabetes. PPARs are thus of interest in type 1 diabetes (T1D) as they represent a novel approach targeting both the pancreas and the immune system. In this review, we examine the role of PPARs in immune responses and beta cell biology and their potential as targets for treatment of T1D.
- 9 January 2020
- Published by Wiley in PPAR Research
- Vol. 2020, 1-11
Open AccessPPARs and the Development of Type 1 Diabetes
Peroxisome proliferator-activated receptors (PPARs) are a family of transcription factors with a key role in glucose and lipid metabolism. PPARs are expressed in many cell types including pancreatic beta cells and immune cells, where they regulate insulin secretion and T cell differentiation, respectively. Moreover, various PPAR agonists prevent diabetes in the non-obese diabetic (NOD) mouse model of type 1 diabetes. PPARs are thus of interest in type 1 diabetes (T1D) as they represent a novel approach targeting both the pancreas and the immune system. In this review, we examine the role of PPARs in immune responses and beta cell biology and their potential as targets for treatment of T1D.